The European Commission is mulling directives from Parliament regarding its criteria for identifying endocrine disruptors, following the latter's rejection of a related EC draft regulation in October. Among shortcomings cited by lawmakers is the absence of a "suspected" ED category, which would be "extremely relevant" in the cosmetics sector, they say.
In October, European Parliament voted in opposition to the first draft regulation that would implement the European Commission's proposed criteria for identifying endocrine disruptors, leaving the EC to contemplate next steps.
Health & Food Safety Commissioner Vytenis Andriukaitis lamented the vote's outcome in a statement, suggesting that "in this...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
